Analyzing Vertex Pharmaceuticals (NASDAQ:VRTX) & Biorestorative Therapies (NASDAQ:BRTX)

Biorestorative Therapies (NASDAQ:BRTX) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Biorestorative Therapies and Vertex Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1	0	0	0	1.00
Vertex Pharmaceuticals	0	2	20	1	2.96

Vertex Pharmaceuticals has a consensus price target of $570.83, suggesting a potential upside of 10.55%. Given Vertex Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Biorestorative Therapies.

Earnings and Valuation

This table compares Biorestorative Therapies and Vertex Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360,000.00	10.33	-$14.24 million	($1.07)	-2.52
Vertex Pharmaceuticals	$12.00 billion	10.92	$3.95 billion	$17.18	30.05

Vertex Pharmaceuticals has higher revenue and earnings than Biorestorative Therapies. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Biorestorative Therapies has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.

Profitability

This table compares Biorestorative Therapies and Vertex Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

Institutional and Insider Ownership

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Biorestorative Therapies on 13 of the 15 factors compared between the two stocks.

About Biorestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.